Teva Pharmaceutical Industries Limited (TEVA)

NYSE:TEVA

TEVA

Teva Pharmaceutical

RESEARCH TOOLSreports

Want to see TEVA full AI Analyst Report?

Teva Pharmaceutical (TEVA) Price & Analysis

7,717 Followers

TEVA Stock Chart & Stats

$32.40

$0.18(0.83%)

At close: Jan 08 4:00 PM EST

$32.40

$0.18(0.83%)

Day’s Range― - ―

52-Week Range$14.99 - $37.35

Previous CloseN/A

Volume1.13M

Average Volume (3M)6.91M

Market Cap

$37.72B

Enterprise Value$54.16B

Total Cash (Recent Filing)$3.74B

Total Debt (Recent Filing)$16.91B

Price to Earnings (P/E)23.9

Beta0.65

Next Earnings

Aug 05, 2026

EPS Estimate

0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.37

Shares Outstanding1,164,638,700

10 Day Avg. Volume5,744,411

30 Day Avg. Volume6,911,192

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)4.53

Price to Sales (P/S)2.08

P/FCF Ratio31.24

Enterprise Value/Market Cap1.44

Enterprise Value/Revenue3.12

Enterprise Value/Gross Profit5.99

Enterprise Value/Ebitda16.56

Forecast

1Y Price Target

$42.11

Price Target Upside29.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)2.26

Revenue Forecast (FY)$16.57B

Bulls Say, Bears Say

Bulls Say

Free Cash Flow StrengthTeva's materially improved cash generation—TTM operating cash flow ~$1.71B and FCF ~$1.17B (+209%)—creates durable capacity to fund R&D, transformation costs, and debt paydown. Consistent FCF supports deleveraging and strategic optionality over the next 2–6 months.

Growing Innovative PortfolioA meaningful shift toward branded, higher-margin products (innovative portfolio >20% of revenue) diversifies Teva away from generics. Strong growth in AUSTEDO, UZEDY and AJOVY supports sustainable margin expansion and steadier revenue mix over multiple quarters.

Transformation Savings & ExecutionCommitted transformation savings (~$700M by 2027, majority realized by end‑2026) indicate structural cost reduction. Realized savings should sustainably lower operating leverage, bolster non‑GAAP margins, and accelerate cash available for debt reduction and reinvestment.

Bears Say

High LeverageSignificant indebtedness (TTM debt ~$16.9B and net debt/EBITDA ~2.42x) constrains strategic flexibility and increases interest and refinancing risk. Deleveraging depends on sustained FCF and realized savings; until achieved, leverage amplifies downside over the medium term.

Generics Revenue VolatilityTeva's generics business remains lumpy and product‑concentration sensitive: the REVLIMID cliff drove large near‑term declines. Continued exposure to single‑molecule cliffs and pricing competition makes revenue and margins volatile absent further portfolio diversification.

Emalex Accounting & Near‑Term P&L HitThe Emalex asset accounting (upfront $700M expensed) plus incremental operating costs will materially depress 2026 reported operating profit and cash metrics. This reduces visible margin progress and can slow deleveraging cadence despite strategic long‑term benefits.

Teva Pharmaceutical News

Teva launches Ahzantive in Europe

Teva (TEVA) announced the launch of Ahzantive, a biosimilar to Eylea, in Europe. The launch of Ahzantive pre-filled...

13m ago

TEVA

Alvotech resubmits AVT05 BLAs to FDA

Alvotech (ALVO) announced the resubmission to the FDA of biologics license applications, or BLAs, for AVT05, a proposed...

4h ago

RDY

ALVO

With $1 Billion Share Sale, Apotex Health Is Canada’s Biggest IPO in Years

There have been a dearth of IPOs in Toronto since 2021. ...

3d ago

IPO

TEVA

Teva commits to Veeva Vault CRM

Veeva Systems (VEEV) announced that Teva Pharmaceuticals (TEVA) has committed to Veeva Vault CRM globally. “We are excited...

8d ago

TEVA

VEEV

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

Teva (TEVA) Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine...

14d ago

TEVA

Einhorn’s DME takes stakes in StubHub, Paramount, buys more Peloton

David Einhorn’s DME Capital Management disclosed in an SEC filing its holdings as of March 31. DME’s new...

18d ago

BHF

Teva put volume heavy and directionally bearish

Bearish flow noted in Teva (TEVA) with 9,316 puts trading, or 8x expected. Most active are Jun-26 30...

21d ago

TEVA

Teva price target raised to $40 from $38 at Barclays

Barclays raised the firm’s price target on Teva (TEVA) to $40 from $38 and keeps an Overweight rating...

28d ago

TEVA

Teva Shareholders Back Board, Executive Pay and Auditor

Teva Pharmaceutical ( ($TEVA) ) just unveiled an update. Teva Pharmaceutical Industries Limited shareholders met on May 28,...

7d ago

TEVA

Teva, Upstart, Bloom, Corning, Seagate Insider Shock

Insiders have been trading these 5 stocks: (($TEVA)), (($UPST)), (($BE)), (($GLW)) and (($STX)). Here is a breakdown of...

26d ago

GLW

Teva Earnings Call Highlights Innovative-Driven Margin Upswing

Teva Pharmaceutical Industries Limited (($TEVA)) has held its Q1 earnings call. Read on for the main highlights of...

30d ago

TEVA

Teva price target raised to $50 from $45 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Teva (TEVA) to $50 from $45 and keeps a Buy...

1M ago

TEVA

Teva price target raised to $40 from $35 at JPMorgan

JPMorgan raised the firm’s price target on Teva (TEVA) to $40 from $35 and keeps an Overweight rating...

1M ago

TEVA

Teva price target raised to $42 from $41 at Piper Sandler

Piper Sandler raised the firm’s price target on Teva (TEVA) to $42 from $41 and keeps an Overweight...

1M ago

TEVA

TEVA FAQ

What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?

Teva Pharmaceutical Industries Limited lowest stock price was $14.99 and its highest was $37.34 in the past 12 months.

What is Teva Pharmaceutical Industries Limited’s market cap?

Teva Pharmaceutical Industries Limited’s market cap is $37.72B.

When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?

Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Aug 05, 2026 which is in 62 days.

How were Teva Pharmaceutical Industries Limited’s earnings last quarter?

Teva Pharmaceutical Industries Limited released its earnings results on Apr 29, 2026. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.471 by $0.059.

Is Teva Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Teva Pharmaceutical Industries Limited pay dividends?

Teva Pharmaceutical Industries Limited pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here

What is Teva Pharmaceutical Industries Limited’s EPS estimate?

Teva Pharmaceutical Industries Limited’s EPS estimate is 0.6.

How many shares outstanding does Teva Pharmaceutical Industries Limited have?

Teva Pharmaceutical Industries Limited has 1,164,638,700 shares outstanding.

What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?

Teva Pharmaceutical Industries Limited reported an EPS of $0.53 in its last earnings report, beating expectations of $0.471. Following the earnings report the stock price went up 11.891%.

Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in TEVA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Teva Pharmaceutical Stock Smart Score

Outperform

Fundamentals

Return on Equity

20.79%

Trailing 12-Months

Asset Growth

4.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva Pharmaceutical (TEVA) Earnings & Revenues

Historic Earnings Reports

TEVA Company Deck

TEVA Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed a predominantly positive strategic and operational picture: strong growth and momentum in the innovative portfolio (AUSTEDO, UZEDY, AJOVY), improving gross margins and cash generation, clear progress on transformation savings and a disciplined, accretive acquisition (Emalex) aligned to the Pivot to Growth strategy. Near-term headwinds include generics comparatives (loss of REVLIMID), accounting and expense impacts from the Emalex asset purchase in 2026, margin reinvestment and some channel/inventory timing uncertainty (notably AUSTEDO destocking and IRA timing). Pipeline milestones present upside but carry binary clinical risk. On balance, the positives — accelerating innovative growth, margin trajectory, balance sheet improvement and clear execution plans — outweigh the near-term and manageable negatives.View all TEVA earnings summaries

TEVA Revenue Breakdown

54.45% North America

32.42% Europe

13.12% International Markets

TEVA Stock 12 Month Forecast

Average Price Target

$42.11

▲(29.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","51":"$51","23.25":"$23.3","32.5":"$32.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.111111111111114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,23.25,32.5,41.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.64,35.82153846153846,37.003076923076925,38.184615384615384,39.36615384615385,40.54769230769231,41.72923076923077,42.91076923076923,44.09230769230769,45.27384615384615,46.45538461538462,47.636923076923075,48.818461538461534,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.64,35.21470085470086,35.78940170940171,36.364102564102566,36.93880341880342,37.513504273504275,38.08820512820513,38.66290598290598,39.23760683760684,39.8123076923077,40.38700854700855,40.961709401709406,41.53641025641026,{"y":42.111111111111114,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.64,35.05230769230769,35.464615384615385,35.87692307692308,36.28923076923077,36.70153846153846,37.113846153846154,37.526153846153846,37.93846153846154,38.35076923076923,38.76307692307692,39.175384615384615,39.58769230769231,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.52,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.77,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.25,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.64,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >